Peptide therapy: what clinics offer, what is proven, cost and insurance
Reviewed 31 sourcesPublished by PepVault
What a peptide therapy clinic offers, from Wegovy to BPC-157: the FDA status and best human trial for each, plus cost, insurance and what to ask first.

- Last reviewed
- Sources
- 31
- Questions
- 6
- Compounds
- 12
The short answer
A peptide therapy clinic sells three kinds of product. FDA-approved drugs such as Wegovy, Zepbound, Egrifta and Vyleesi have large trials behind one labelled use. Compounded copies are not FDA-approved, and FDA does not check them before they are sold. Research peptides such as BPC-157, ipamorelin and thymosin alpha-1 have no US approval and little human data. Before you pay, ask which kind each offering is.
Evidence: Ranges from high (large randomized trials behind Wegovy, Zepbound and tesamorelin's one use) to very low (three small studies of BPC-157 with no placebo group).

What is peptide therapy?
Peptide therapy is a clinic's name for treatment with peptides, short chains of amino acids that act as signals in the body. The menu mixes three very different things. Some are FDA-approved drugs: FDA reviewed trials showing they work for a named use, and the label lists that use. Some are compounded: a pharmacy makes its own version of the drug, usually for one patient's prescription, and FDA does not review compounded drugs for safety, effectiveness or quality before they are sold4. The rest are research peptides with no approved product in the US at all.
The gap between those groups is the whole story. Semaglutide has a 1,961-person trial behind it10; BPC-157's largest published human study is a phone survey of 16 patients16. Whether any of them suits you is a treatment decision, and that decision is the prescriber's.

What do peptide therapy clinics offer, and what is known about each?
The usual menu, with each offering's FDA status as of November 2026 and the best human study we could find at its primary source:
| Offering | What it is | FDA status (November 2026) | Best human evidence | Evidence level |
|---|---|---|---|---|
| Semaglutide (Wegovy, Ozempic) | A GLP-1 drug, a weekly shot or a daily pill, that slows the stomach and quiets appetite | Approved: Wegovy since June 2021; today's label covers weight, heart risk in adults with heart disease, and a liver disease (MASH)830 | STEP 1: 1,961 adults, 68 weeks: weight down 14.9% against 2.4% on placebo10 | High |
| Tirzepatide (Zepbound, Mounjaro) | A weekly shot acting on two gut-hormone receptors, GIP and GLP-1 | Approved: Zepbound since November 2023; today's label covers weight, and sleep apnea with obesity930 | SURMOUNT-1: 2,539 adults, 72 weeks: weight down 20.9% on 15 mg against 3.1% on placebo11 | High |
| Compounded semaglutide or tirzepatide | A pharmacy-made version of the same ingredient, often in a vial | Not approved; FDA's shortage-era leeway ended in 20256 | None tested as compounded; FDA had 990 adverse event reports for compounded semaglutide and over 730 for tirzepatide by May 31, 20267 | Not studied as sold |
| Sermorelin | A copy of the first 29 amino acids of the hormone that tells the pituitary to release growth hormone | Approved as Geref in 1990 for children short of growth hormone; now discontinued12 | 110 children with growth hormone deficiency, open-label: growth rose from 4.1 to 8.0 cm a year by 6 months13 | Moderate, in children |
| Tesamorelin (Egrifta) | A longer-lasting version of the same releasing hormone, a daily shot | Approved since November 2010 for one use: excess belly fat in adults with HIV and lipodystrophy; the label says it is not for weight loss1430 | 412 people with HIV, 26 weeks: deep belly fat down 15.2% against up 5.0% on placebo15 | High, for that use |
| BPC-157 | A 15-amino-acid fragment of a protein in gastric juice | No approved product; FDA once placed it in category 2 (significant safety risks), the nomination was withdrawn, and FDA's safety page still lists it2; HHS's October 30, 2026 draft compounding policy came after (see the next section)31 | Three small studies with no placebo group: 16 knee-pain patients, 12 women with bladder pain, 2 adults given it by IV161718 | Very low |
| Ipamorelin and CJC-1295 | A ghrelin-like growth hormone releaser, and a releasing-hormone analogue sold with or without a long-acting tail (DAC), often sold together | No approved product; ipamorelin in category 2 of FDA's 503B policy since September 29, 2023; for CJC-1295 FDA cites raised heart rate and a whole-body reaction of widened blood vessels2 | Ipamorelin by IV after bowel surgery, 114 patients: no difference from placebo20; CJC-1295 in its long-acting DAC form raised growth hormone 2- to 10-fold for 6 days or more after one shot in healthy adults21 | Low, hormone levels only |
| PT-141 (bremelanotide, Vyleesi) | A melanocortin drug injected as needed | Approved June 2019 for premenopausal women with low sexual desire that causes distress; not for men or after menopause2230 | Two trials, 1,267 women, 24 weeks: desire score up 0.35 points more than placebo; nausea in 40% against 1%2223 | Moderate, small effect |
| GHK-Cu | A copper-carrying three-amino-acid peptide, used on skin and injected | No approved drug; category 1 (under evaluation) except as an injection, which is on FDA's safety page12 | Skin products after laser resurfacing, 13 patients: no measured difference in wrinkles, higher satisfaction24 | Low |
| NAD+ injections and drips | A coenzyme every cell uses to make energy | No approved drug product; category 1 (under evaluation)130 | A pilot infusion: blood NAD+ did not rise for the first 2 hours of a 6-hour drip25 | Very low for any outcome |
| Thymosin alpha-1 | A thymus peptide that acts on immune cells | No US approval; nominated, then withdrawn; FDA cites a risk of immune reactions230 | TESTS: 1,106 adults with sepsis in China: 28-day deaths 23.4% against 24.1% on placebo, no difference26 | Moderate, and negative for sepsis |
Two things the table shows. The approved drugs earned their labels for specific uses, so a clinic offering tesamorelin for general fat loss is prescribing off-label, outside the use FDA reviewed. And where research peptides have been tested against placebo, ipamorelin after bowel surgery and thymosin alpha-1 in sepsis, they did no better2026.
Commonly reported: people starting a GLP-1 describe nausea and a much smaller appetite in the first weeks, easing as the dose settles; on growth hormone releasers, water retention and tingling hands; and after any injection, a small red bump at the site that fades within a day.
What does compounded mean, and what are 503A and 503B?
A compounded peptide comes from one of two kinds of compounder. A 503A pharmacy is a state-licensed pharmacy that compounds for individual prescriptions, and its state board of pharmacy oversees it day to day. A 503B outsourcing facility can make larger batches, is overseen mainly by FDA and must follow the same manufacturing standards as drug makers4. FDA publishes the list of registered outsourcing facilities, updated as of November 17, 202629.
For an ingredient with no approved drug, FDA sorts nominations into categories. Category 1 is under evaluation, and FDA does not intend to act against a pharmacy that meets its conditions; category 2 holds substances with significant safety risks, and category 3 those nominated without enough data3. As of May 14, 2026, NAD+ and non-injected GHK-Cu were in category 1 and kisspeptin-10 in category 21. In July 2026 FDA put BPC-157, TB-500, MOTS-c and four other peptides before its compounding advisory committee19. On October 30, 2026, HHS published a draft enforcement discretion policy: while FDA's rulemaking on the 503A list goes on, HHS does not intend to act against a state-licensed pharmacy, federal facility or physician compounding the peptides named in its Appendix A31. It is not an approval, binds neither HHS nor the public, and may be revisited on a safety or quality problem31. FDA's category list and safety page predate it (May 14 and April 22, 2026). Our FDA peptide panel guide names the peptides the policy covers.
Compounded semaglutide and tirzepatide grew during the shortages. FDA declared them over, and its leeway for copies ended for tirzepatide on March 5, 2025 at 503A pharmacies (after a court ruling) and March 19 at 503B facilities; for semaglutide on April 24 and May 22, 20256. Our guide on compounded GLP-1s against the brands covers what differs in the vial.
Is peptide therapy covered by insurance?
The approved brands can be; the clearest public rule is Medicare's. From July 1, 2026, Medicare's GLP-1 Bridge covers Wegovy, Zepbound KwikPens and Foundayo for a $50 copay a month, for adults who meet its weight and health criteria; it does not cover single-dose Zepbound vials or pens, and people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are outside it27. Its list names no compounded drug27.
Five rows in the table have no approved US product and sermorelin's brand is discontinued, so there is no brand a plan could list for them. Private plans set their own lists: ask the plan whether the exact drug, for your use, is covered, and ask the clinic for an itemised receipt.
How much does peptide therapy cost?
Only the makers publish prices. In November 2026 Novo Nordisk's own pharmacy sells Wegovy pens without insurance for $349 a month at any dose up to 2.4 mg and $399 for the 7.2 mg pen; new patients pay $199 a month for two fills of the 0.25 and 0.5 mg starting doses through December 31, 2026. The Wegovy pill runs $149 to $299 a month by dose28. Our GLP-1 cost guide sets out Zepbound and the other brands.
Clinics set their own prices for compounded and research peptides, and no public source tracks them, so ask for the full monthly total: the drug, the visit, the labs and the shipping.
What should you ask a clinic before you start?
- Ask who prescribes it, and whether that person reviews your history and medicines before writing it.
- Ask whether each product is an FDA-approved brand or compounded. FDA says to ask your health care professional if you are unsure5.
- If it is compounded, ask the pharmacy's name and whether it is a state-licensed 503A pharmacy or a 503B outsourcing facility; you can find a 503B in FDA's list29. FDA advises filling prescriptions at a state-licensed pharmacy7.
- Ask the FDA status of the ingredient itself: approved, category 1, or on FDA's safety-risks list12.
- Ask for the dose written in milligrams, with the vial's strength on the label.
- Ask which blood tests come before you start and when they are repeated, and ask for copies.
- Ask how the drug ships. FDA advises not using an injectable GLP-1 that arrives warm7.
- Ask how to report a side effect. FDA asks for reports to your health care professional and to FDA5.
PepVault logs each dose with its compound, amount and injection site, and reminds you when the next one is due. Log it in PepVault
Its bloodwork log keeps the clinic's lab results over time, and the doctor's report puts your doses and labs on one page for the prescriber. Log it in PepVault
Severe stomach pain that does not ease, trouble breathing, or swelling of the face or throat after a dose is a reason to get medical care the same day.
Sources
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (updated May 14, 2026). fda.gov
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026). fda.gov
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (read November 20, 2026). fda.gov
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (read November 20, 2026). fda.gov
- U.S. Food and Drug Administration. Human Drug Compounding: Consumer and Health Care Professional Information (content current as of June 9, 2026). fda.gov
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (dated entries Oct 2, 2024 to Apr 1, 2026; content current as of April 1, 2026). fda.gov
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026). fda.gov
- Wegovy (semaglutide) injection and tablets. Prescribing information, Novo Nordisk. DailyMed, revised 6/2026, section 1. dailymed.nlm.nih.gov
- Zepbound (tirzepatide) injection. Prescribing information, Eli Lilly. DailyMed, revised 8/2026, section 1. dailymed.nlm.nih.gov
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. PubMed 33567185
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. PubMed 35658024
- U.S. Food and Drug Administration. Drugs@FDA: Geref (sermorelin acetate), NDA 019863, approved December 28, 1990; marketing status discontinued. accessdata.fda.gov
- Thorner M et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81:1189-96. PubMed 8772599
- Egrifta SV (tesamorelin) for injection. Prescribing information, Theratechnologies. DailyMed, SPL version 9, published July 31, 2026, section 1. dailymed.nlm.nih.gov
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-70. PubMed 18057338
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27:8-13. PubMed 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30:12-17. PubMed 39325560
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31:20-24. PubMed 40131143
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of August 6, 2026). fda.gov
- Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29:1527-34. PubMed 25331030
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91:799-805. PubMed 16352683
- Vyleesi (bremelanotide injection). Prescribing information. DailyMed, updated November 5, 2026, sections 1 and 6.1. dailymed.nlm.nih.gov
- Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134:899-908. PubMed 31599840
- Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8:252-9. PubMed 16847171
- Grant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci. 2019;11:257. PubMed 31572171
- Wu J et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. PubMed 39814420
- Medicare.gov. Weight loss drugs: the Medicare GLP-1 Bridge (read November 20, 2026). medicare.gov
- Novo Nordisk. NovoCare: Wegovy savings offer and self-pay prices (read November 20, 2026). novocare.com
- U.S. Food and Drug Administration. Registered Outsourcing Facilities (content current as of November 17, 2026). fda.gov
- U.S. Food and Drug Administration. openFDA Drugs@FDA records: Wegovy NDA 215256 (approved June 4, 2021), Zepbound NDA 217806 (November 8, 2023), Egrifta 022505 (November 10, 2010), Vyleesi NDA 210557 (June 21, 2019); no record for thymalfasin or nadide (searched November 20, 2026). api.fda.gov
- Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability. Federal Register 91 FR 68526-68527, October 30, 2026 (FR Doc. 2026-22192, docket HHS-OASH-2026-0496). federalregister.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.